Evropska unija -
slovenščina -
EMA (European Medicines Agency)
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
nuvaxovid
novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. uporaba tega cepiva mora biti v skladu z uradnimi priporočili. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
anastrozol synthon 1 mg filmsko obložene tablete
synthon bv - anastrozol - filmsko obložena tableta - anastrozol 1 mg / 1 tableta - anastrozol
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
bicacel 150 mg filmsko obložene tablete
genthon bv - bikalutamid - filmsko obložena tableta - bikalutamid 150 mg / 1 tableta - bikalutamid
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
bikalutamid synthon 50 mg filmsko obložene tablete
synthon bv - bikalutamid - filmsko obložena tableta - bikalutamid 50 mg / 1 tableta - bikalutamid
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
gervaton 160 mg filmsko obložene tablete
synthon bv - valsartan - filmsko obložena tableta - valsartan 160 mg / 1 tableta - valsartan